Aadi Bioscience Beheer

Beheer criteriumcontroles 2/4

De CEO Aadi Bioscience is Dave Lennon, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.14M, bestaande uit 7.5% salaris en 92.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.093% van de aandelen van het bedrijf, ter waarde $ 44.82K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 3.3 jaar.

Belangrijke informatie

Dave Lennon

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	7.5%
Dienstverband CEO	1.1yrs
Eigendom CEO	0.09%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Analyse CEO-vergoeding

Hoe is Dave Lennon's beloning veranderd ten opzichte van Aadi Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Compensatie versus markt: De totale vergoeding ($USD 2.14M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 656.26K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Dave te vergelijken met de prestaties van het bedrijf.

CEO

Dave Lennon (53 yo)

1.1yrs

Tenure

US$2,135,687

Compensatie

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Lennon	President	1.1yrs	US$2.14m	0.093% $ 44.8k
Scott Giacobello	CFO, Treasurer	3yrs	US$1.97m	0% $ 0
Stephen Rodin	Senior VP of Legal & General Counsel	2.8yrs	geen gegevens	geen gegevens
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.4yrs	geen gegevens	geen gegevens
Bryan Ball	Chief Technical Operations Officer	2.3yrs	geen gegevens	0.41% $ 196.0k

2.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AADI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Lennon	President	1.1yrs	US$2.14m	0.093% $ 44.8k
Caley Castelein	Independent Chairman of the Board	3.3yrs	US$258.91k	0.080% $ 38.6k
Emma Reeve	Independent Director	3.2yrs	US$240.91k	0% $ 0
Anupam Dalal	Independent Director	3.3yrs	US$235.91k	0.0046% $ 2.2k
Karin Hehenberger	Independent Director	3.3yrs	US$227.41k	0% $ 0
Richard Maroun	Independent Director	7.8yrs	US$240.91k	0% $ 0
Mohammad Hirmand	Independent Director	1.7yrs	US$345.60k	0% $ 0
Behzad Aghazadeh	Independent Director	3.3yrs	US$225.41k	0% $ 0

3.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AADI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Aadi Bioscience Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Founder notifies of intention to sell stock

Recent updates

Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Consensus estimates of losses per share improve by 12%

Price target decreased by 14% to US$10.00

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Consensus revenue estimates decrease by 14%, EPS upgraded

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 112%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes